Medivation, Inc.
201 Spear Street
3rd Floor
San Francisco,
CA 94105
United States - Map
Phone: 415-543-3470
Fax: 415-543-3411
Web Site: http://www.medivation.com
| Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimers disease, Huntingtons disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimers disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntingtons disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer. Medivation, Inc. was founded in 2003 and is based in San Francisco, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. David Hung M.D., 51
Chief Exec. Officer, Pres and Exec. Director |
$
877.00K | N/A | Mr. C. Patrick Machado , 44
Chief Financial Officer and Sr. VP |
$
606.00K | N/A | Dr. Lynn Seely M.D., 49
Chief Medical Officer |
$
606.00K |
$
539.00K | Mr. Rohan Palekar , 43
Chief Commercial Officer |
$
597.00K | N/A | Dr. Robert Zimmerman S.D.,
Preclinical Consultant |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.16% Nasdaq 
0.27 (0.91%) 
Profile
